Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Inspire Investing LLC

Inspire Investing LLC trimmed its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 64.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,813 shares of the specialty pharmaceutical company’s stock after selling 15,985 shares during the quarter. Inspire Investing LLC’s holdings in Collegium Pharmaceutical were worth $341,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Gladius Capital Management LP acquired a new position in shares of Collegium Pharmaceutical in the 2nd quarter valued at $32,000. nVerses Capital LLC raised its position in shares of Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,600 shares during the period. GAMMA Investing LLC boosted its holdings in Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 792 shares during the last quarter. CWM LLC grew its position in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 736 shares during the period. Finally, Sheaff Brock Investment Advisors LLC acquired a new stake in Collegium Pharmaceutical during the first quarter worth about $204,000.

Analysts Set New Price Targets

COLL has been the topic of several research analyst reports. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. HC Wainwright lifted their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Truist Financial increased their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. StockNews.com upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Trading Down 1.3 %

COLL opened at $38.44 on Friday. The firm has a market capitalization of $1.26 billion, a P/E ratio of 16.02 and a beta of 0.94. The firm’s 50 day moving average is $37.65 and its 200-day moving average is $35.48. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. Collegium Pharmaceutical, Inc. has a 52-week low of $20.95 and a 52-week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. The firm had revenue of $145.28 million for the quarter, compared to analyst estimates of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The firm’s revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.13 EPS. Analysts expect that Collegium Pharmaceutical, Inc. will post 5.79 EPS for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the transaction, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares in the company, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by company insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.